Intestinal Ameboma (ICD-11: 1A36.01) - Complete Clinical Coding Guide

Q: What is the difference between Entamoeba histolytica and Entamoeba dispar?

*Entamoeba histolytica* and *Entamoeba dispar* are distinct species of amoebae that are morphologically identical under light microscopy but differ significantly in pathogenicity. *E. histolytica* is pathogenic, capable of invading the intestinal mucosa causing colitis, dysentery, ameboma, and extraintestinal complications such as liver abscess. *E. dispar*, on the other hand, is considered non-pathogenic or of minimal pathogenicity, living as a commensal in the intestinal lumen without causing

1. Introduction

Intestinal ameboma represents a chronic and granulomatous complication of Entamoeba histolytica infection, characterized by the formation of an inflammatory tumor-like mass in the colon wall. This condition constitutes a rare, yet clinically significant, manifestation of invasive amebiasis, occurring when the host's inflammatory response to parasitic infection results in segmental thickening of the intestinal wall with formation of granulation tissue.

The clinical importance of intestinal ameboma resides mainly in its potential to mimic colonic neoplasms, leading to considerable diagnostic challenges. The mass may present as an obstructive or semi-obstructive lesion, frequently confused with colorectal adenocarcinoma, Crohn's disease, or intestinal tuberculosis during initial evaluation. This similarity with other serious pathologies makes proper recognition of this entity fundamental to avoid unnecessary surgical interventions.

From an epidemiological perspective, ameboma is more prevalent in regions with poor sanitary conditions and limited access to potable water, where fecal-oral transmission of E. histolytica is facilitated. Although intestinal amebiasis is common in endemic areas, the development of ameboma represents only a small fraction of cases, estimated to occur in less than 1% of E. histolytica infections.

Correct coding of intestinal ameboma using the ICD-11 code 1A36.01 is critical for multiple reasons. First, it enables appropriate epidemiological tracking of this specific complication, differentiating it from other forms of amebiasis. Second, it facilitates hospital resource planning, since ameboma management frequently requires a multidisciplinary approach involving gastroenterologists, infectious disease specialists, and occasionally surgeons. Third, accurate documentation aids in studies of therapeutic efficacy and analysis of clinical outcomes. Finally, appropriate coding ensures adequate reimbursement by health services and contributes to the quality of medical records.

2. Correct ICD-11 Code

Code: 1A36.01

Description: Intestinal ameboma

Parent category: 1A36.0 - Intestinal infection by Entamoeba

The code 1A36.01 in the ICD-11 system was designated specifically to identify cases of intestinal ameboma, a chronic granulomatous presentation of infection by Entamoeba histolytica. This code is hierarchically positioned under the broader category 1A36.0, which encompasses all forms of intestinal infection caused by Entamoeba species.

The hierarchical structure of ICD-11 allows code 1A36.01 to capture with precision the specific nature of this condition. While the parent category (1A36.0) encompasses acute, subacute, and chronic manifestations of intestinal amebiasis, code 1A36.01 is reserved exclusively for cases where there is confirmation of granulomatous mass formation in the intestinal wall.

This code should be used when there is clinical, radiological, or histopathological evidence of an inflammatory tumor-like lesion caused by E. histolytica. The specificity of this code is particularly valuable in contexts where differentiation between acute forms of amebic colitis and this chronic granulomatous manifestation is essential for therapeutic planning and prognosis.

Appropriate implementation of this code requires clear understanding of the distinctive characteristics of ameboma in relation to other manifestations of intestinal amebiasis, as well as familiarity with the diagnostic criteria that confirm this specific clinical entity.

3. When to Use This Code

The code 1A36.01 should be applied in specific clinical scenarios where there is diagnostic confirmation of intestinal ameboma. Below, we present detailed practical situations:

Scenario 1: Colonic Mass with Parasitological Confirmation

Patient presenting with symptoms of partial intestinal obstruction, with colonoscopy revealing circumferential mass in the ascending colon or cecum. Biopsy demonstrates granulomatous inflammatory process with identification of E. histolytica trophozoites in tissue or presence of amebic antigens by immunohistochemistry. Serological tests for anti-E. histolytica antibodies are positive. In this context, code 1A36.01 is appropriate because there is confirmation of both the granulomatous nature of the lesion and the amebic etiology.

Scenario 2: Tumor-like Lesion in Endemic Area with Response to Specific Treatment

Patient from an endemic region for amebiasis presents with palpable mass in the right lower quadrant of the abdomen, with computed tomography showing segmental thickening of the colon wall with extension of 5-8 centimeters. Parasitological stool examinations identify cysts of E. histolytica. Amebic serology strongly positive. After treatment with metronidazole followed by paromomycin, there is significant regression of the mass. The therapeutic response confirms the diagnosis of ameboma, justifying the use of code 1A36.01.

Scenario 3: Surgical Finding with Histopathological Confirmation

Patient submitted to exploratory laparotomy for suspected colonic neoplasia. During the procedure, a mass is identified in the transverse colon with inflammatory characteristics. Histopathological analysis by frozen section and subsequently definitive examination reveals amebic granuloma with focal necrosis and presence of parasites. This scenario requires code 1A36.01, as the diagnosis was established through direct anatomopathological confirmation.

Scenario 4: Partial Intestinal Obstruction with Imaging Diagnosis

Patient with history of bloody diarrhea treated three months ago now presents with subacute symptoms of constipation alternating with diarrhea and abdominal distension. Barium enema or virtual colonoscopy demonstrates stenotic lesion in the descending colon with characteristics of "apple-core lesion." Molecular tests (PCR) for E. histolytica are positive in stool samples. Serology confirms recent infection. Code 1A36.01 is appropriate due to the combination of clinical, imaging, and laboratory findings consistent with ameboma.

Scenario 5: Resolved Differential Diagnosis

Patient initially investigated for inflammatory bowel disease or colonic neoplasia. Colonoscopy shows ulcerated mass in the cecum. Multiple biopsies are initially inconclusive. Serological tests for amebiasis requested later return strongly positive. Histopathological review with special stains (PAS, trichrome) identifies trophozoites. Code 1A36.01 should be used after definitive diagnostic elucidation.

Scenario 6: Post-Dysentery Presentation

Patient with documented history of acute amebic colitis 2-4 months ago, treated inadequately or incompletely, returns with symptoms of localized abdominal discomfort and altered bowel habits. Imaging examination reveals mass formation at the previously affected site. This represents a classic scenario of progression from acute amebiasis to ameboma, fully justifying the use of code 1A36.01.

4. When NOT to Use This Code

Incorrect application of code 1A36.01 can occur in several situations where there is diagnostic confusion or inadequate documentation:

Acute Amebic Colitis without Mass Formation: Patients presenting with acute bloody diarrhea with confirmation of E. histolytica in stool, but without evidence of granulomatous lesion or tumor mass on colonoscopy or imaging studies, should be coded as 1A36.00 (Acute amebiasis) and not 1A36.01. The absence of a tumor component is a fundamental exclusion criterion.

Amebic Liver Abscess: Although caused by the same parasite, amebic liver abscess represents an extraintestinal complication of amebiasis and has different specific coding. It should not be confused with intestinal ameboma, even when both conditions coexist (in this case, both codes should be used separately).

Other Causes of Colonic Mass: Colorectal neoplasms, Crohn's disease with inflammatory mass formation, intestinal tuberculosis, intestinal lymphoma, and colonic actinomycosis can mimic ameboma radiologically and endoscopically. Code 1A36.01 should only be applied after definitive exclusion of these conditions through parasitologic, serologic, or histopathologic confirmation of amebic etiology.

Asymptomatic Colonization by E. dispar: Microscopic identification of "amoebas" in stool may represent Entamoeba dispar, a morphologically identical but non-pathogenic species. Without confirmation of E. histolytica through specific methods (antigen tests, PCR, serology) and without demonstrable lesion, code 1A36.01 should not be used.

Scars or Stenoses Post-Amebiasis: Patients with a previous history of amebiasis who develop fibrotic or cicatricial stenoses without active inflammatory component or current parasite presence should be coded as sequelae, not as active ameboma. Code 1A36.01 implies active pathologic process.

Exclusive Extraintestinal Amebiasis: Rare cases of cutaneous, pulmonary, or cerebral amebiasis without documented intestinal involvement should not receive code 1A36.01, which is specific for intestinal lesions.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

Diagnostic confirmation of intestinal ameboma requires a multimodal approach. Initially, the presence of an intestinal tumor-like lesion must be established through imaging methods or endoscopy. Computed tomography frequently reveals segmental wall thickening of the intestine with heterogeneous enhancement, while colonoscopy may demonstrate an ulcerated, friable, or stenotic mass.

Etiological confirmation is fundamental and can be obtained through: (1) histopathological identification of E. histolytica trophozoites in biopsies; (2) detection of E. histolytica-specific antigens in stool or tissue; (3) positive serology for anti-E. histolytica antibodies, particularly useful in non-endemic areas; (4) E. histolytica-specific PCR in clinical samples.

Clinical history should include assessment of risk factors such as travel or residence in endemic areas, inadequate sanitary conditions, immunosuppression, and previous history of amebiasis dysentery. The typical clinical presentation includes localized abdominal pain, altered bowel habits, and occasionally a palpable mass.

Step 2: Verify Specifiers

Although code 1A36.01 does not have formal subclassifications in ICD-11, clinical documentation should include important specifiers: precise anatomical location (cecum, ascending colon, transverse, descending, sigmoid), approximate lesion size, presence or absence of complications (obstruction, imminent perforation, bleeding), and treatment status (newly diagnosed, under treatment, refractory).

Severity can be classified as mild (small mass without obstructive symptoms), moderate (symptomatic mass with partial obstruction), or severe (complete obstruction, perforation, or systemic complications). Duration of symptoms helps characterize the chronicity of the condition.

Step 3: Differentiate from Other Codes

Differentiation from 1A36.00 (Acute Amebiasis): The fundamental distinction lies in the presence of granulomatous mass formation. Acute amebiasis (1A36.00) typically presents with diffuse colitis, multiple flask-shaped ulcerations, acute bloody diarrhea, and absence of tumor-like lesion. Ameboma (1A36.01) is characterized by a localized lesion, palpable or visible mass on imaging, more indolent course, and frequently a history of previous acute episode.

Chronology also helps: acute symptoms lasting less than 4 weeks generally represent acute amebiasis, while subacute or chronic presentations with mass formation suggest ameboma. Treatment response also differs: acute colitis responds rapidly with symptom resolution in days, while ameboma requires prolonged treatment with gradual mass regression over weeks to months.

Step 4: Required Documentation

Adequate documentation to justify code 1A36.01 should include:

Mandatory Checklist:

Detailed description of the lesion (location, size, characteristics)
Diagnostic method used (colonoscopy, computed tomography, surgery)
Results of parasitological tests (stool, biopsy)
Serological results for E. histolytica
Exclusion of main differential diagnoses
Assessment of associated complications
Specific therapeutic plan for ameboma

Appropriate Record: "Patient presents with a mass in the ascending colon approximately 6 cm in size, identified on colonoscopy, with biopsy revealing granulomatous inflammatory process. Serology for E. histolytica positive with elevated titers. PCR in stool confirms E. histolytica. Computed tomography demonstrates segmental wall thickening of the intestine without signs of perforation. Diagnosis: Intestinal ameboma (ICD-11: 1A36.01). Treatment initiated with metronidazole."

6. Complete Practical Example

Clinical Case

A 42-year-old male farmer presents to medical care with a complaint of right lower quadrant abdominal pain lasting 6 weeks, associated with alternating episodes of diarrhea and constipation. He reports that approximately 3 months ago he presented with bloody diarrhea that was treated symptomatically with antidiarrheals, without further investigation. He denies current fever but mentions occasional night sweats and unintentional weight loss of approximately 4 kg.

On physical examination, he appears in good general condition, afebrile, with a palpable and tender mass in the right lower quadrant of the abdomen, firm in consistency, with limited mobility. There are no signs of peritonitis or significant abdominal distension.

Initial laboratory tests show mild anemia (hemoglobin 11.2 g/dL), mild leukocytosis (11,500/mm³) with eosinophilia (8%), and elevated C-reactive protein. Parasitological examination of stool in three samples identifies cysts of E. histolytica in one of the samples.

Computed tomography of the abdomen reveals concentric thickening of the cecal wall and distal ascending colon, measuring approximately 7 cm in length, with heterogeneous enhancement after contrast, with no evidence of perforation or fluid collections. There is no significant lymphadenopathy or hepatic lesions.

Colonoscopy demonstrates an ulcerated, friable, circumferential mass in the cecum, with partial luminal narrowing. The colonoscope is able to traverse the lesion with difficulty. Multiple biopsies are obtained. Histopathological analysis reveals granulomatous inflammation with focal necrosis, mixed infiltrate of inflammatory cells, and, on trichrome staining, identification of E. histolytica trophozoites in the tissue.

Serology for E. histolytica returns strongly positive, with elevated IgG antibody titers. Tumor markers (CEA, CA 19-9) are within normal limits. PCR specific for E. histolytica in stool sample confirms the presence of the pathogenic parasite.

Step-by-Step Coding

Criteria Analysis:

Presence of confirmed tumor mass: Yes - palpable mass on physical examination, visualized on computed tomography and colonoscopy
Intestinal location: Yes - cecum and ascending colon
Confirmation of amebic etiology: Yes - multiple methods (parasitological, histopathological, serological, molecular)
Granulomatous nature: Yes - confirmed histopathologically
Exclusion of other causes: Yes - normal tumor markers, histological characteristics incompatible with neoplasia or other infections

Code Selected: 1A36.01 - Intestinal Ameboma

Complete Justification:

The code 1A36.01 is appropriate in this case because all diagnostic criteria for intestinal ameboma are present. The clinical presentation with palpable mass, subacute/chronic symptoms, and history of prior dysentery is typical. Confirmation through multiple methods (direct visualization, histopathology, serology, and PCR) definitively establishes the amebic etiology of the granulomatous lesion.

The differentiation from 1A36.00 (acute amebiasis) is clear due to the presence of tumor formation and chronic course, rather than acute diffuse colitis. The exclusion of colonic neoplasia was adequately performed through histopathology and tumor markers.

Complementary Codes:

D50.0 (Anemia due to iron deficiency secondary to chronic blood loss) - if anemia is significant and requires specific treatment
K56.6 (Partial intestinal obstruction) - if there is clear evidence of compromise of intestinal transit

Final Documentation:

"Intestinal ameboma of the cecum and ascending colon (ICD-11: 1A36.01), confirmed by colonoscopy with biopsy showing amebic granuloma with identification of E. histolytica trophozoites, positive serology and confirmatory PCR. Lesion measuring 7 cm with partial obstruction. Treatment initiated with metronidazole 750 mg PO 3 times daily for 10 days, followed by paromomycin 500 mg PO 3 times daily for 7 days. Follow-up scheduled with control colonoscopy in 3 months to assess therapeutic response."

7. Related Codes and Differentiation

Within the Same Category

1A36.00: Acute Amebiasis

The distinction between acute amebiasis (1A36.00) and ameboma intestinale (1A36.01) is fundamental for appropriate coding and represents one of the most common challenges in clinical practice.

When to use 1A36.00: This code is appropriate for cases of acute amebic colitis characterized by abrupt onset of bloody diarrhea (dysentery), diffuse abdominal cramping, tenesmus, and fecal urgency. Colonoscopy typically reveals multiple colonic ulcerations, especially in the cecum and ascending colon, with edematous surrounding mucosa. There is no tumor mass formation. Symptoms generally last less than 4 weeks and respond rapidly to antiamebic treatment.

When to use 1A36.01: This code should be reserved for chronic or subacute presentations where there is formation of a granulomatous tumor-like lesion. The history frequently includes a previous episode of dysentery. Symptoms are more indolent: localized abdominal pain, alteration of bowel habits without profuse diarrhea, and occasionally a palpable mass. Endoscopy or imaging demonstrates a localized lesion, frequently stenotic. Response to treatment is slower, with gradual regression of the mass.

Main Difference: The presence or absence of granulomatous mass formation is the fundamental differentiating criterion. Acute amebiasis represents mucosal invasion with ulceration, whereas ameboma represents chronic inflammatory response with organized granuloma.

Differential Diagnoses

Colorectal Adenocarcinoma: May present with symptoms and radiologic findings virtually identical to ameboma. Differentiation requires biopsy with careful histopathologic analysis, tumor markers, and specific tests for E. histolytica. Positive amebic serology and response to antiamebic treatment favor ameboma.

Crohn's Disease: Can cause segmental thickening of the intestinal wall with formation of an inflammatory mass. Differentiation is based on histologic characteristics (non-caseating granulomas without parasites in Crohn's disease), absence of positive amebic serology, and distribution pattern (Crohn's disease frequently affects the terminal ileum and is discontinuous).

Intestinal Tuberculosis: Can also form granulomatous masses, especially in the ileocecal region. Differentiation requires culture for mycobacteria, PCR for Mycobacterium tuberculosis, tuberculin test, and exclusion of evidence of pulmonary tuberculosis. Histopathology shows caseating granulomas in tuberculosis versus identification of parasites in ameboma.

Intestinal Lymphoma: May present as a colonic mass. Immunohistochemistry is definitive, showing lymphoid markers (CD20, CD3) in lymphoma, absent in ameboma.

8. Differences with ICD-10

In the ICD-10 system, intestinal ameboma was coded as A06.3 - Intestinal ameboma. Although the nomenclature is similar, there are important differences in structure and application between the systems.

Main Changes in ICD-11:

The transition to ICD-11 brought greater specificity in hierarchical structure. While ICD-10 used A06.3 as an independent code within category A06 (Amebiasis), ICD-11 organizes ameboma as 1A36.01, subordinated to category 1A36.0 (Intestinal infection by Entamoeba), which in turn is within the broader chapter of intestinal infectious diseases.

ICD-11 introduces greater clarity in differentiating between acute forms (1A36.00) and chronic complications such as ameboma (1A36.01), whereas ICD-10 had less specific categories (A06.0 for acute amebic dysentery and A06.1 for chronic intestinal amebiasis, with ameboma in a separate category).

Practical Impact:

For coders and healthcare professionals, the main practical change is the need for familiarization with the new numerical structure (1A36.01 instead of A06.3). Hospital information systems and electronic health records need to be updated to reflect the new coding.

ICD-11 facilitates data aggregation on Entamoeba infections, allowing more robust analyses of different disease manifestations. The clearer hierarchical structure aids in information retrieval and epidemiological studies.

For purposes of continuity of medical records, it is important to document that cases previously coded as A06.3 in ICD-10 should be considered equivalent to 1A36.01 in ICD-11, although individual review is recommended to ensure that updated diagnostic criteria are met.

9. Frequently Asked Questions

How is the definitive diagnosis of intestinal ameboma made?

The definitive diagnosis of intestinal ameboma requires a multimodal approach combining clinical, radiological, endoscopic, and laboratory evidence. Initially, imaging studies (computed tomography or magnetic resonance imaging) identify the tumor-like lesion with segmental thickening of the intestinal wall. Colonoscopy allows direct visualization and biopsy sampling, which are essential for histopathological analysis. Etiological confirmation is obtained through: microscopic identification of E. histolytica trophozoites in biopsies (using special stains such as trichrome or PAS), detection tests for E. histolytica-specific antigens in stool or tissue, serology for anti-E. histolytica antibodies (particularly useful in non-endemic areas, with sensitivity greater than 90% in cases of invasive amebiasis), and molecular PCR to differentiate E. histolytica from E. dispar. The combination of multiple methods increases diagnostic accuracy and allows exclusion of important differential diagnoses such as colorectal neoplasia and intestinal tuberculosis.

Is treatment available in public health systems?

Antiamebic medications used in the treatment of intestinal ameboma are generally available in public health systems in most countries, especially in regions endemic for amebiasis. Standard treatment consists of two components: a tissue agent (metronidazole or tinidazole) to eliminate invasive trophozoites, followed by a luminal agent (paromomycin, iodoquinol, or diloxanide furoate) to eradicate intestinal cysts. Metronidazole, the first-line medication, is included in the World Health Organization's List of Essential Medicines and is widely available. Paromomycin is also on this list. In public health systems, these medications are frequently provided free of charge or at subsidized cost to patients with confirmed diagnosis. However, availability may vary between different regions and health systems. In areas with limited resources, access to advanced diagnostic methods (such as PCR or specific antigen tests) may be more challenging than access to the medications themselves.

How long does treatment last and what is the prognosis?

Medical treatment of intestinal ameboma typically lasts 2-3 weeks, divided into two phases. The first phase consists of 7-10 days of metronidazole (750 mg three times daily) or tinidazole (2 g daily for 3 days), followed by the second phase with a luminal agent such as paromomycin (500 mg three times daily for 7 days). However, complete regression of the tumor mass is a gradual process that may take 3-6 months, requiring periodic clinical and radiological follow-up. The prognosis is generally excellent with appropriate treatment, with cure rates exceeding 90%. Most patients show symptomatic improvement within 1-2 weeks after starting treatment, although mass regression is slower. Complications such as complete intestinal obstruction or perforation may require surgical intervention in fewer than 5% of cases. Follow-up includes control colonoscopy at 3-6 months to document lesion regression. Recurrence is rare (less than 5%) when treatment is completed appropriately and there is complete parasite elimination. Factors influencing prognosis include lesion size, presence of complications at diagnosis, patient's immunological status, and adherence to complete treatment.

Can this code be used in medical certificates and sick leave?

Yes, the ICD-11 code 1A36.01 can and should be used in medical certificates, work leave documentation, and absence from work records when appropriate. Intestinal ameboma is a legitimate medical condition that frequently requires absence from work activities, especially during the initial phase of treatment when symptoms are most pronounced. The typical duration of absence ranges from 1-3 weeks, depending on symptom severity, presence of complications, and the nature of the patient's professional activities. Workers in positions requiring intense physical effort or those involved in food handling may require longer periods. Proper documentation should include the ICD-11 code, a brief description of the condition, and justification for the requested absence period. It is important to note that, for reasons of medical confidentiality, some patients may prefer documentation that does not specify complete diagnostic details, in which case the higher category code (1A36.0) may be used. Labor legislation in different jurisdictions may have specific requirements regarding the level of detail necessary in medical certificates.

What are the risks of not treating an ameboma adequately?

Inadequate treatment or absence of treatment for intestinal ameboma can result in significant complications. The most common complication is progression to complete intestinal obstruction, which may require emergency surgical intervention. Intestinal perforation, although rare, is a potentially fatal complication that can occur in untreated cases, leading to peritonitis and sepsis. Chronic intestinal bleeding can result in severe anemia, particularly in patients with already compromised nutritional status. There is also risk of hematogenous dissemination of the parasite, which may cause amebic liver abscess (the most common extraintestinal complication of amebiasis) or, more rarely, cerebral or pulmonary amebiasis. Persistence of infection without adequate treatment keeps the patient as a source of transmission to other individuals through cyst elimination in feces. Additionally, delayed or incorrect diagnosis may result in unnecessary surgeries when the ameboma is confused with colonic neoplasia. Incomplete treatment (use of tissue agent without subsequent luminal agent) can result in infection recurrence, with therapeutic failure rates of up to 40-60% when metronidazole alone is used.

Can ameboma be confused with colon cancer?

Yes, intestinal ameboma is frequently confused with colorectal adenocarcinoma, representing one of the main diagnostic challenges in gastroenterology. Both conditions can present with remarkably similar clinical and radiological features: palpable abdominal mass, altered bowel habits, weight loss, anemia, and stenotic lesion on imaging studies. On colonoscopy, both may appear as ulcerated, friable masses with luminal narrowing. This similarity frequently leads to extensive investigations and, in some cases, unnecessary exploratory surgeries. Differentiation requires a systematic approach including: careful epidemiological history (travel or residence in endemic areas, sanitary conditions, previous episode of dysentery), serological tests for E. histolytica (usually negative in cancer), detailed histopathological analysis of biopsies with special stains to identify parasites, and tumor markers (CEA, CA 19-9, which are typically normal in ameboma). In doubtful cases, a pragmatic approach is to initiate antiamebic treatment and assess response: ameboma will show clinical and radiological regression in weeks to months, while neoplasms do not respond. This strategy can avoid unnecessary surgeries, although it should be used with caution and rigorous follow-up.

Can people who had ameboma develop the condition again?

Yes, reinfection is possible after successful treatment of intestinal ameboma, especially if the patient continues to be exposed to risk factors for E. histolytica transmission. Unlike some infections where durable protective immunity develops, amebiasis does not confer permanent immunity. Cured patients can be reinfected if exposed again to the parasite through contaminated water or food. For this reason, preventive measures are fundamental: access to treated drinking water, adequate sanitation, hand hygiene, and care with food preparation. In endemic areas, the risk of reinfection is substantial if environmental conditions are not modified. Patients with a history of ameboma should be educated about prevention and advised to seek early medical attention if they develop gastrointestinal symptoms suggestive of amebiasis. The development of ameboma after reinfection appears to be less common than in initial infection, possibly due to some degree of residual immune response, although definitive studies on this aspect are limited. Periodic medical follow-up may be recommended for patients in high transmission areas, particularly those with persistent risk factors.

What is the difference between Entamoeba histolytica and Entamoeba dispar?

Entamoeba histolytica and Entamoeba dispar are distinct species of amoebae that are morphologically identical under light microscopy but differ significantly in pathogenicity. E. histolytica is pathogenic, capable of invading the intestinal mucosa causing colitis, dysentery, ameboma, and extraintestinal complications such as liver abscess. E. dispar, on the other hand, is considered non-pathogenic or of minimal pathogenicity, living as a commensal in the intestinal lumen without causing tissue invasion or significant disease. It is estimated that E. dispar is approximately 10 times more prevalent than E. histolytica in human populations. The distinction between the two species is crucial because microscopic identification of "amoebae" in stool may represent either species. Patients infected only with E. dispar do not require antiamebic treatment (although some specialists recommend treatment with luminal agent to eliminate the parasite and prevent transmission). Definitive differentiation requires specialized methods: E. histolytica-specific antigen detection tests, molecular PCR, or serology (anti-E. histolytica antibodies are produced only in response to invasive E. histolytica infection, not by E. dispar). This distinction is particularly important to avoid unnecessary treatment and for accurate epidemiological studies on the true prevalence of pathogenic amebiasis.

Conclusion

The ICD-11 code 1A36.01 for intestinal ameboma represents an essential tool for accurate documentation of this chronic granulomatous manifestation of Entamoeba histolytica infection. Correct application of this code requires clear understanding of the distinctive clinical characteristics of ameboma, including the formation of intestinal tumor-like mass, typically subacute or chronic course, and the need for diagnostic confirmation through complementary methods. Proper differentiation of other forms of amebiasis, particularly acute colitis (1A36.00), and important differential diagnoses such as colorectal neoplasia and intestinal tuberculosis, is fundamental for appropriate coding. With timely diagnosis and adequate treatment, the prognosis of intestinal ameboma is excellent, emphasizing the importance of correct recognition of this condition and its proper documentation through the appropriate ICD-11 code.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Intestinal Ameboma

Share